文献速递甲状腺与浅表介入US

超声引导下射频消融与微波消融治疗T1N0M0甲状腺乳头状癌的结局比较:一项回顾性队列研究

Comparative outcomes of ultrasound-guided radiofrequency ablation vs. microwave ablation for patients with T1N0M0 papillary thyroid carcinoma: a retrospective cohort study.
PubMed 文献 · Eur Radiol · 2025-01-21

该回顾性队列纳入1111例单发T1N0M0甲状腺乳头状癌患者,射频消融组894例、微波消融组215例,经倾向性评分匹配后比较疾病进展、无复发生存率、体积缩小率及并发症,结果显示两种消融方式在上述结局上均无显著差异。

要点

  • 倾向性评分匹配后,射频消融与微波消融的疾病进展率分别为3.3%与3.7%,无显著差异(p=0.793)。
  • 匹配后两组无复发生存率分别为96.7%与96.3%(p=0.821),体积缩小率分别为99.3±3.0%与98.3±8.5%(p=0.865)。
  • 作者建议热消融时应由具备丰富 modalities 知识的合格且经验丰富的医师操作。

核心结论

  • 射频消融与微波消融治疗T1N0M0甲状腺乳头状癌的临床结局无显著差异,术式选择可能取决于医师经验与当地中心资源。

研究设计与样本

  • 回顾性队列研究,纳入1111例单发T1N0M0甲状腺乳头状癌患者,射频消融组894例、微波消融组215例,由经验丰富的医师操作,采用倾向性评分匹配比较两组结局。

诊断标准与关键数值

  • 中位随访41.7±12.6个月,总体疾病进展率2.1%、淋巴结转移率0.7%、复发肿瘤率1.2%、持续肿瘤率0.2%。
  • 匹配后射频消融组 vs 微波消融组:疾病进展3.3% vs 3.7%(p=0.793),淋巴结转移1.4% vs 1.9%(p=1.000)。
  • 匹配后射频消融组 vs 微波消融组:复发肿瘤1.4% vs 1.9%(p=1.000),持续肿瘤0.5% vs 0%(p=0.317)。
  • 匹配后射频消融组 vs 微波消融组:无复发生存率96.7% vs 96.3%(p=0.821),体积缩小率99.3±3.0% vs 98.3±8.5%(p=0.865)。
  • 匹配后射频消融组 vs 微波消融组:肿瘤消失率87.9% vs 81.4%(p=0.061),并发症率1.4% vs 1.9%(p=1.000)。

临床应用与阅片要点

  • 对于单发T1N0M0甲状腺乳头状癌,射频消融与微波消融的疾病进展、无复发生存率、体积缩小率、肿瘤消失率及并发症均无显著差异。
  • 作者认为射频消融与微波消融的选择可能取决于医师经验与当地中心资源。
  • 作者建议进行热消融时,应由具备丰富 modalities 知识的合格且经验丰富的医师操作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare the clinical outcomes between radiofrequency ablation (RFA) and microwave ablation (MWA) for the treatment of T1N0M0 papillary thyroid carcinoma (PTC) in a large cohort.

MATERIALS AND METHODS: This retrospective study included 1111 patients with solitary T1N0M0 PTC treated with RFA (n = 894) or MWA (n = 215) by experienced physicians. A propensity score matching was used to compare disease progression, including lymph node metastases (LNM), recurrent tumors and persistent tumors, recurrence-free survival (RFS), volume reduction ratio (VRR), and complications between the RFA and MWA groups. The subgroup outcomes of T1a and T1b tumors treated with RFA and MWA were also compared.

RESULTS: During a mean follow-up period of 41.7 ± 12.6 months, the overall incidence rates of disease progression, LNM, recurrent tumors, and persistent tumors were 2.1%, 0.7%, 1.2%, and 0.2%, respectively. Eight patients (0.7%) experienced transient voice change and recovered within 3 months. After 1:1 matching, there were no significant differences in disease progression (3.3% vs. 3.7%, p = 0.793), LNM (1.4% vs. 1.9%, p = 1.000), recurrent tumor (1.4% vs. 1.9%, p = 1.000), persistent tumors (0.5% vs. 0%, p = 0.317), RFS rates (96.7% vs. 96.3%, p = 0.821), VRR (99.3 ± 3.0% vs. 98.3 ± 8.5%, p = 0.865), tumor disappearance rate (87.9% vs. 81.4%, p = 0.061) and complications (1.4% vs. 1.9%, p = 1.000) between the RFA and MWA groups. For T1a and T1b tumors, clinical outcomes were comparable between RFA and MWA.

CONCLUSIONS: RFA and MWA did not show significant differences in clinical outcomes for T1N0M0 PTC. The choice between RFA and MWA could depend on physician expertise and resources of local center resources. A qualified and experienced physician with extensive knowledge of the modalities is recommended when thermal ablation is performed.

KEY POINTS: Question With radiofrequency ablation (RFA) and microwave ablation (MWA) used worldwide for T1N0M0 papillary thyroid carcinoma (PTC), is one of them superior to the others? Findings There were no significant differences in disease progression, recurrence-free survival, volume reduction ratio, tumor disappearance, or complications between techniques for solitary T1N0M0 papillary thyroid carcinoma. Clinical relevance The choice between RFA and MWA could depend on physician expertise and resources of the local center resources. A qualified and experienced physician with extensive knowledge of the modalities is recommended when thermal ablation is performed.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yan L, Yang Z, Jing H, et al. Comparative outcomes of ultrasound-guided radiofrequency ablation vs. microwave ablation for patients with T1N0M0 papillary thyroid carcinoma: a retrospective cohort study. Eur Radiol. 2025. PMID: 39836201. doi:10.1007/s00330-024-11286-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。